
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. demonstrates a positive outlook due to the strengthening efficacy profile of its lead program, TARA-002, which has shown 100% durability and an 80% salvage rate upon re-induction, based on recent 6-month data. The company's intravenous choline chloride therapy has shown significant improvements in liver health compared to placebo in Phase 2 trials, highlighting its potential impact on intestinal failure associated liver disease (IFALD). With its robust safety profile and differentiated positioning in the non-muscle invasive bladder cancer (NMIBC) landscape, TARA-002 is well-positioned to compete effectively in the market, bolstering investor confidence in Protara's future growth prospects.
Bears say
Protara Therapeutics reported a net loss of $12.7 million, or $0.48 per share, in the fourth quarter of 2024, indicating ongoing financial challenges. Despite the promising early signals from its lead program, TARA-002, the stock remains significantly undervalued compared to peers, which raises concerns regarding market confidence and investor sentiment. Additionally, the competitive landscape in the NMIBC market may create hurdles, especially given the high bar set by other therapies and the critical supply issues affecting key treatment components like BCG.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares